The CXCR4 blockade has been shown to modulate the tumor microenvironment by reducing stromal desmoplasia, facilitating T-lymphocyte infiltration, and alleviating immune suppression—mechanisms that can help overcome resistance to ICIs and improve therapeutic outcomes in various malignancies [5,59]. This evidence concerns the gene CXCR4 and neoplasm.